VHL stands for Von Hippel-Lindau disease, which is a rare, genetic multi-system disorder. It is caused by a mutation in the VHL gene, which is a tumor suppressor gene that regulates cell growth and division. VHL is associated with the growth of non-cancerous tumors in certain parts of the body, including the brain, spinal cord, eyes, kidneys, pancreas, and adrenal glands. The tumors can cause a range of symptoms, depending on their size and location, such as vision problems, deafness in one ear, high blood pressure, balance problems, impaired vision, muscle weakness, headache, backache, neck pain, and more. Individuals with VHL are also at a higher risk than normal for certain types of cancer, especially kidney cancer. Treatment for VHL varies according to the location and size of the tumor, and the objective of treatment is to treat the tumors before they grow to a size large enough to cause permanent problems by putting pressure on the brain or spinal cord. Prognosis depends on the number, location, and complications of the tumors, and untreated VHL may result in blindness and/or permanent brain damage. With early detection and treatment, the prognosis is significantly improved.